New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. (CST) of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. This novel antibody discovery technology, named NG-XMTTM, harnesses the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an immunized animal. As described in the May print issue of Nature Biotechnology [30, 447 - 452 (2012)], NG-XMTTM technology enables the isolation of monoclonal antibodies with antigen-specific activities that recapitulate or surpass those of the original affinity-purified polyclonal antibodies found in the sera of immunized rabbits and mice.

“CST is exploring all avenues to bring this technology to market and to impact patients' lives.”

"Our NG-XMTTM proteomics-based technology is faster and more efficient than traditional hybridoma-based methods, " said Roberto D. Polakiewicz, Ph.D., CST Chief Scientific Officer. "Moreover, our proprietary and patent pending technology can be applied to the development of therapeutically relevant human monoclonal antibodies for vaccine development and for understanding basic questions in immunology. CST has long been an industry leader in the development and manufacture of high performance antibodies for basic and clinical research, and we are excited to announce this breakthrough in monoclonal antibody technology."

"NG-XMT™ technology is ready for commercialization," said Fenel M. Eloi, CST Chief Operating Officer. "CST is exploring all avenues to bring this technology to market and to impact patients' lives."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cell Signaling Technology. (2019, June 20). New discovery platform for antigen-specific monoclonal antibodies. News-Medical. Retrieved on February 20, 2024 from https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx.

  • MLA

    Cell Signaling Technology. "New discovery platform for antigen-specific monoclonal antibodies". News-Medical. 20 February 2024. <https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx>.

  • Chicago

    Cell Signaling Technology. "New discovery platform for antigen-specific monoclonal antibodies". News-Medical. https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx. (accessed February 20, 2024).

  • Harvard

    Cell Signaling Technology. 2019. New discovery platform for antigen-specific monoclonal antibodies. News-Medical, viewed 20 February 2024, https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors